Actuate Therapeutics Inc
NASDAQ:ACTU · NASDAQ Global Market
+$0.06 today
Vol 0.03M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-280.5%
avg -6645.2%
ROIC
-270.1%
avg -1158.9%
ROA
-158.4%
avg -343.9%
Analysis
ROA is currently the strongest return metric at -158.4% versus its period average of -343.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel Schmitt | Chief Executive Officer, President & Director | $712,329.00 | — | 64 | $237,000.00 | 0.99% |
Andrew Mazar | Co-Founder & Chief Operating Officer | $552,150.00 | — | 64 | $105,000.00 | 0.44% |
Paul J. Lytle | Chief Financial Officer | $514,425.00 | — | 58 | $105,000.00 | 0.44% |
Alan Kozikowski | Scientific Founder and Advisor | — | — | 76 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$3.00M
Sells
1
$1.62M
Net Sentiment
+$1.38M
Net buying
Most Active
Bios Equity COF, LP
2 transactions
Analysis
Insiders reported 6 buys worth $3.00M and 1 sells worth $1.62M over the last 12 months. That adds up to net buying of $1.38M. Bios Equity COF, LP was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Nkarta, Inc.
NASDAQ:NKTX
$195.68M
Alector, Inc.
NASDAQ:ALEC
$174.86M
Molecular Partners AG
NASDAQ:MOLN
$148.22M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$129.13M
PepGen Inc.
NASDAQ:PEPG
$120.70M
Vor Biopharma Inc.
NASDAQ:VOR
$103.52M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$71.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$62.56M
VistaGen Therapeutics, Inc.
VTGN
$22.68M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages ACTU?
Actuate Therapeutics Inc (ACTU) lists 4 active executives. The top listed executive is Alan Kozikowski, Scientific Founder and Advisor.
Are ACTU insiders buying or selling?
Recent insider activity shows net buying of $7.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.